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ABSTRACT  
 Membrane-type matrix metalloproteinases (MT-MMPs) constitute a subfamily of 6 
distinct membrane-associated MMPs. Although the contribution of MT1-MMP during different 
steps of cancer progression has been well documented, the significance of other MT-MMPs is 
rather unknown. We have investigated the involvement of MT4-MMP, a glycosylphosphatidyl-
inositol (GPI) anchored protease in breast cancer progression. Interestingly, 
immunohistochemical analysis demonstrates that MT4-MMP production at protein level is 
strongly increased in epithelial cancer cells of human breast carcinomas as compared to normal 
epithelial cells. Positive staining for MT4-MMP is also detected in lymph node metastases. In 
contrast, quantitative RT-PCR analysis reveals similar MT4-MMP mRNA levels in human 
breast adenocarcinomas and normal breast tissues. Stable transfection of MT4-MMP cDNA in 
human breast adenocarcinoma MDA-MB-231 cells does not affect in vitro cell proliferation or 
invasion, but strongly promotes primary tumor growth and associated metastases in RAG-1 
immunodeficient mice. We provide for the first time evidence that MT4-MMP over-production 
accelerates in vivo tumor growth, induces enlargement of intratumoral blood vessels and is 
associated with increased lung metastases. These results identify MT4-MMP as a new putative 
target to design anti-cancer strategies. 
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INTRODUCTION   
 Matrix Metalloproteinases (MMPs) are a family of zinc-binding endopeptidases that can 
degrade virtually all extracellular matrix components as well as a growing number of other 
modulators of cell functions (1-4). Although most MMPs are secreted as soluble enzymes, 6 of 
them are membrane-type MMPs (MT-MMPs) which are associated with the cell membrane by 
either a transmembrane domain (MT1-, MT2-, MT3-, MT5-MMPs) or a glycosylphosphatidyl-
inositol (GPI) anchor (MT4-, MT6-MMPs) (5). 
MT1-MMP, the first discovered member of this subfamily, was initially described as an 
activator of pro-MMP2 (6). MT1-MMP plays critical roles in cell migration, cell invasion, 
physiological and pathological remodeling of ECM (5, 7). It is a multifunctional protease for 
which an increasing number of substrates have been identified, including pro-MMP2, pro-
MMP13, extracellular matrix components, cell surface receptors, growth factors, chemokines, 
adhesion and signaling molecules (2, 5). Its implication in tumor growth, invasion and 
angiogenesis is now well documented (5, 8-11). A pro-angiogenic effect of MT1-MMP has 
been linked, at least in part, to an up-regulation of vascular endothelial growth factor (VEGF) 
(12, 13).  
Although much emphasis has been placed on understanding the biochemical features 
and functions of MT1-MMP (5), little attention has been given to the implication of other MT-
MMPs in cancer progression and angiogenesis. Different MT-MMPs (MT2-, MT3-, MT5-
MMPs) can activate pro-MMP2 but less efficiently than MT1-MMP (5, 14, 15). Despite being 
able to bind TIMP-2 (tissue inhibitor of metalloproteinase-2), MT4- and MT6-MMPs are rather 
inefficient at activating pro-MMP2 (16-18). Since its original isolation from human breast 
carcinoma (19), MT4-MMP has been detected in several human cancers, including gliomas 
(20), prostate (21) and breast carcinomas (19). However, its localization and implication during 
human breast cancer progression is currently unknown. The inability of MT4-MMP to activate 
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pro-MMP2 and the lack of a cytoplasmic tail in this cell surface GPI-anchored protease 
suggests that MT4-MMP displays different functions than MT1-MMP. Its few known 
substrates are fibrinogen, fibrin and proTNF-α and ADAMTS-4 (a disintegrin and 
metalloproteinase with thrombospondin-like motif-4) (16, 22, 23).  
The aim of this study was to explore the expression of MT4-MMP in human breast 
carcinomas by RT-PCR and immunohistochemical analyses and to investigate its putative role 
in cancer progression through its over-expression in human breast adenocarcinomas cells. We 
provide evidence that MT4-MMP is produced at higher levels by human mammary carcinoma 
cells than by normal epithelial cells. We demonstrate for the first time that its over-expression 
in human breast cancer cells promotes primary tumor growth leading to increased lung 
metastases. A link between MT4-MMP and metastatic dissemination of human breast cancers 
is further supported by its strong expression in human lymph node metastases. 
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MATERIAL AND METHODS 
Human tissue samples 
Human breast samples were obtained from tumor banks of Center for Experimental 
Cancer Research (University of Liège) and of School of Biological Sciences, University of East 
Anglia (United Kingdom). Breast tumor samples were obtained from 63 patients with invasive 
breast ductal carcinomas who underwent surgery. Normal breast tissues were obtained from 21 
patients who underwent reduction mammoplasty. Twelve metastatic and 6 normal lymph nodes 
from 4 patients were also collected. Breast tumors were reviewed regarding histopathologic 
type based on the World Health Organization (WHO) classification. All cancer samples were 
characterized by more than 70 % cancer cell composition. Total RNA was extracted from 
frozen samples with RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany) according to 
manufacturer’s instructions.  
Cell culture 
Human breast cancer MDA-MB-231 cells obtained from American Type Culture 
Collection (Manassas, VA) were grown to 80% confluence in Dulbecco’s Modifed Eagle’s 
Medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 
U/ml of penicillin and 100 µg/ml of streptomycin at 37°C in a 5% CO2 humid atmosphere. All 
culture reagents were purchased from Gibco-Life Technologies (Invitrogen Corporation, 
Paisley, Scotland).  
Stable transfection of MDA-MB-231 cells with human MT4-MMP cDNA  
Parental MDA-MB-231 cells were stably transfected by electroporation (250 V, 960 
µF) with pcDNA3-neo vector containing only the neomycin resistance gene (control plasmid) 
or with the same plasmid carrying the full-length human MT4-MMP cDNA (pcDNA3-MT4) 
(19, 24). Selection was performed under G418 pressure (1.5 mg/ml) (Life Technologies) and 
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screening of clones was based on RT-PCR analysis to determine MT4-MMP expression. Stable 
transfectants were maintained in medium containing G418 (500 µg/ml).  
Preparation of proteins cell extracts, conditioned media and total RNAs 
Conditioned media of cells for ELISA were prepared by seeding cells (2.5 x 105) onto 6 
well-plates for 24 h in 3 ml of DMEM with serum, followed by incubating cells for 48 h in 1.5 
ml of serum-free DMEM. Similarly, conditioned media for rat aortic rings assay were prepared 
by culturing 106 cells in 100 mm diameter Petri dishes (Falcon, Beckton Dickinson, Lincoln 
Park, New Jersey). Cells were grown in 8 ml of DMEM with serum for 24 h and then, in 6 ml 
of serum-free DMEM for 48 h. Conditioned media were harvested, clarified by centrifugation 
and stored frozen at -20°C. Total protein cell extracts were prepared from cell monolayers 
incubated in RIPA buffer (25). Protein concentration was determined by using the DC protein 
Assay Kit (Bio-rad Laboratories, Hercules, CA). Total RNAs were extracted from cell 
monolayer using High Pure RNA isolation kit (Roche Diagnostic Applied Science, Mannheim, 
Germany). 
Semi-quantitative Reverse Transcriptase-PCR analysis  
RT-PCR was performed on 10 ng of total RNA extracted from cells using a GeneAmp 
Thermostable rTth Reverse Transcriptase RNA PCR kit (Applied Biosystems, Foster City, CA) 
following manufacturer’s instructions. Specific pairs of primers (Eurogentec, Seraing, 
Belgium) for human MT4-MMP were designed as follows: forward 5'-
AAGGAGACAGGTACTGGGTGTTC-3'; reverse 5'-TCGCCATCCAGCACTTTCCAGTA-3'. 
Cycles (36) of amplification were run for 15 s at 94 °C, 20 s at 68 °C and 30 s at 72 °C.  
Quantitative Reverse Transcriptase-PCR analysis 
Reverse Transcription and Quantitiative RealTime PCR were conducted as described in Nuttall 
et al. (20). Sequences for the primers and the probe specific to MT4-MMP were designed as 
follows: forward 5’-GCGGGTATCCTTCCTCTACGT-3’; reverse 5’-
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CAGCGACCACAAGATCGTCTT-3’; probe 5’-FAM-ATTGTCCTTGAACACCCAGTAC 
CTGTCTCCTTTAA-TAMRA-3’. 
Western blotting analysis 
Samples (20 µg of total cell protein extracts) were separated under reducing conditions 
on 10 % polyacryamide gels and transferred onto PVDF membranes (NEN, Boston, MA). 
Membranes were blocked overnight at 4 °C with Gloria milk powder (5 %, w/v), Tween 20 
(0.05 %, v/v) in phosphate buffered saline (PBS). Antigenic bands were detected by exposing 
the membranes to primary antibody [anti-human MT4-MMP sheep polyclonal antibody (16) or 
anti-MT1-MMP mouse monoclonal antibody (12)], followed by incubation with a secondary 
horseradish peroxidase (HRP)-conjugated rabbit anti-sheep antibody or goat anti-mouse 
antibody (1:1,000, DakoCytomation, Glostrup, Denmark). Signals were detected using an 
enhanced chemiluminescence (ECL) kit (PerkinElmer Life Sciences, Boston, MA), according 
to manufacturer’s instructions and actin production level was determined as loading control.  
In vitro growth rate 
MDA-MB-231 cells (104) were seeded in triplicate in 24-well plates and maintained in 
standard culture conditions. Fluorimetric DNA titration was performed on samples harvested 
every day and used as an indicator of cell density (26). The average cell density from triplicate 
experiments was determined as a function of time. 
In vitro invasion assay: Boyden chamberCell invasion was assayed using a Transwell cell 
culture chamber inserts system (Costar, NY) with 6.5-mm polycarbonate filters (8 µm pore 
size) as previously described (25). Briefly, 6 × 104 cells were allowed to migrate through 
inserts, pre-coated with 25 µg of matrigel, for 20h. Cells having reached the lower surface of 
the filters were stained with Giemsa and counted in 30 random fields per insert (400-fold 
magnification). Each clone was tested three times in triplicate. 
Enzyme-linked immunosorbent assay for quantitative determination of VEGF 
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VEGF (VEGF165 and VEGF121 isoforms) levels were determined in 100 µl of 
conditioned media (dilution 1:4) in triplicate using a human VEGF DuoSet ELISA 
development kit (R&D Systems, Minneapolis, MN) following manufacturer’s instructions. 
VEGF amounts were normalized to total protein concentration of conditioned media. 
In vitro angiogenesis: mouse aortic rings assay with conditioned media  
In vitro angiogenesis was studied by culturing rings of rat aorta in three-dimensional 
collagen gels as previously described (25). Images were captured on a Zeiss microscope at day 
6 and morphometric analysis was performed on a “Sun SPARC30” workstation with the 
software “Visilog 5.0” from Noesis. After generating binary images, the number and the 
maximal length of the outgrown microvessels were automatically performed (27). 
In vivo tumorigenicity 
Subconfluent MDA-MB-231 cells were trypsinized, resuspended in serum-free medium 
(5 x 106 cells/ml) and mixed with an equal volume of cold Matrigel according to Noël et al. 
(28). Cell suspension (106 cells in 400 µl) was injected subcutaneously into RAG-1 
immunodeficient mice (29) at both flanks (5 or 6 mice/clone in each assay). Tumor growth was 
assessed by measuring the length and width of tumors every 3-4 days. Tumor volumes were 
estimated using the formula (length) X (width)2 X 0.4 (28). Results are expressed as the mean 
of tumor volumes for each experimental group. Tumor incidence represents the percentage of 
mice bearing tumor larger than 200 mm3 at day 45. 
Immunohistochemistry 
To unmask antigens on paraffin sections (5-µm thick), slides were incubated for 1 hr at 
80 °C in citrate buffer pH6 (Dako, Glostrup, Denmark, S2031), autoclaved for 11 min at 126 
°C in Target Retrieval Solution (Dako, S1699) or in citrate buffer (pH6), micro-waved for 4 x 5 
min at 350 W in Target Retrieval Solution for MT4-MMP, Ki-67, α-smooth muscle actin 
(SMA), von Willebrand factor (vWF) stainings, respectively. Endogenous peroxydase was 
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subsequently blocked by 3 % H2O2/ H2O for 20 min and non-specific binding was prevented by 
incubation in PBS/BSA 10 % (Fraction V, Acros Organics, NJ) for 1 h (for MT4-MMP and Ki-
67) or in normal goat serum for 30 min (for SMA and vWF). Sections were then incubated with 
a rabbit polyclonal anti-MT4-MMP (Sigma, M3684, 1:300) overnight at 4 °C, a mouse 
monoclonal anti-Ki-67 (Dako, clone MIB-1, M7240, 1:100), a mouse monoclonal anti-SMA 
(Dako, M0801, 1:100) or a rabbit polyclonal anti-vWF (Dako, A00602, 1:200) for 1 hr at room 
temperature (RT). Slides were then incubated with a HRP-conjugated second antibody 
(Envision System Labeled Polymer-HRP, Dako, K4001, ready to use) (for Ki-67) or with a 
biotinylated second antibody (Dako, E0433, 1:400) at room temperature for 30 min, followed 
by incubation with a Strepatavidin/HRP complex (Dako, P0397, 1:500) at RT for 30 min (for 
MT4-MMP, SMA and vWF). Coloring was performed with 3-3’diaminobenzidine 
hydrochloride (DAB, Dako, K3468) for 3 min. Slides were finally counter-stained with 
hematoxylin and mounted with Eukitt medium for microscope observation. Omission of the 
first antibody served as negative control.  
Quantification of MT4-MMP production in human breast cancer  
For quantitative measurement of MT4-MMP immunostaining, an original automatic 
computer-assisted image analysis was applied on 50 representative sections by using software 
“Aptelion 3-2” from Adsis. Staining density was determined by measuring the ratio between 
the surface of immunostaining and the surface of total mammary epithelium. The staining 
intensity (1/µm2) is defined as the sum of grey level intensities of each pixels characterizing 
stained region divided by surface of epithelium. 
Lung metastasis assay from subcutaneous tumors  
Paraffin sections of mice lung (5 mice/clones) were immuno-stained for human KI-67 
protein (30). Metastatic foci were counted in 65 histological fields per section at 200-fold 
magnification. Incidence of metastasis is expressed as the percentage of mice with detectable 
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metastatic cells in the lungs. Severity of metastasis was scored as: minimal (score 1° = 
metastatic nodule involving less than 3 stained cells), medium (score 2° = metastatic nodule 
composed of 3 to 20 stained cells), or extensive involvement (score 3° = metastatic nodule 
including more than 20 stained cells).  
Statistical analysis 
We assessed statistical differences between both experimental groups using Mann-
Whitney test. Fisher’s exact test was used to compare metastasis incidences. In both tests, P-
values < 0.05 (*) were considered as significant. Statistical analyses were carried out using the 
Prism 4.0 software (GraphPad, San Diego, CA).  
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RESULTS  
MT4-MMP is produced by human breast epithelial cancer cells  
 MT4-MMP expression levels were first determined by real time qRT-PCR analysis in 
63 breast adenocarcinomas and 21 normal breast tissue samples. MT4-MMP transcripts were 
expressed at similar levels in breast carcinomas and normal breast tissues (Fig. 1A). MT4-
MMP production in human breast tissues was further investigated by immunohistochemistry 
revealing a strong homogenous staining of tumor cells in all breast tumor samples analyzed (n 
= 17) (Fig. 1B). Staining was detected in few interstitial cells presumably inflammatory cells 
(Fig. 1B). In normal breast tissues (n = 11), epithelial cells were stained at variable intensities 
ranging from a negative to a moderate positivity, myoepithelial cells being unreactive. 
Quantitative assessment of MT4-MMP staining was performed by computer-assisted image 
analysis. A strong enhancement of both density and intensity staining was observed in tumor 
samples (Fig. 1C). 
Immunohistochemical analysis was also performed in normal and metastatic human 
breast cancer lymph nodes. Interestingly, in opposite to normal human breast lymph nodes, 
invading cancer cells as well as inflammatory cells of metastatic lymph nodes (11/12) were 
strongly immunostained for MT4-MMP (Fig. 1B).  
The important MT4-MMP immunostaining of tumor epithelial cells in human cancer 
tissues prompted us to study the contribution of this membrane-associated enzyme in cancer 
progression and angiogenesis. Based on the mRNA expression profile of different human 
breast cancer cell lines (data not shown), MDA-MB-231 cells which expressed MT4-MMP at 
very low levels [in accordance with (19, 20, 31)] were selected for transfection with human 
MT4-MMP cDNA.  
Generation of MDA-MB-231 cells stably expressing MT4-MMP    
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Parental MDA-MB-231 cells were stably transfected with control pcDNA3-neo vector 
(clones C) or with pcDNA3-neo containing human MT4-MMP cDNA (clones M). Four clones 
over-expressing MT4-MMP (M2, M3, M10, M14) and 4 control clones (C4, C12, C14, C15) 
were selected according to MT4-MMP expression at mRNA (Fig. 2A) and protein (Fig. 2B) 
levels. MT4-MMP over-expressing clones were found to stably express MT4-MMP. Western 
blot analysis revealed 2 bands at the expected molecular weight (~ 64 kDa), the upper one 
being the pro-form and the lower one being the active-form (16). Clone M2, which was 
characterized by the highest MT4-MMP production (Fig. 2) was confirmed to express both 
active- and pro-forms by loading a lower amount of protein in Western blot analysis. In all 
selected clones, MT1-MMP protein expression was not affected by transfection with MT4-
MMP cDNA (data not shown). 
MT4-MMP over-expression does not affect in vitro cell proliferation or invasion  
 Clones were then compared for their in vitro proliferation and invasive capacities 
through different matrices. MT4-MMP over-expression did not significantly affect in vitro 
growth rate as illustrated in Fig. 3A (P > 0.05). The in vitro invasion potential of all clones was 
then evaluated in Boyden chambers by using inserts coated with Matrigel. The numbers of 
invading cells was independent of MT4-MMP production (P > 0.05) (data not shown). 
Similarly, the capacity of MT4-MMP transfectants to migrate through gelatin-coated inserts or 
to invade type I collagen gel-coated inserts did not differ to that of control clones (data not 
shown).  
Gelatin zymography (data not shown) revealed that MT4-MMP production by MDA-
MB-231 clones, either treated or not with concanavalin-A, did not lead to a higher activation of 
exogenous pro-MMP2 [consistent with (16)]. 
MT4-MMP over-expression does not affect in vitro angiogenesis or VEGF expression  
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  Since MT1-MMP has been demonstrated to affect in vitro and in vivo angiogenesis 
through a modulation of VEGF-A expression (12), we measured VEGF production of all 
clones by RT-PCR analysis and ELISA. VEGF mRNA levels in clones expressing MT4-MMP 
were undistinguishable from those of control clones (data not shown). Furthermore, similar 
amounts of proteins were detected by ELISA in medium conditioned by MT4-MMP over-
expressing clones (1365 +/- 100 pg/ml) and control clones (1369 +/- 344 pg/ml). Similarly, RT-
PCR analysis of other angiogenic molecules (VEGF-B, -C, -D and PlGF) did not reveal any 
difference between clones expressing or not MT4-MMP (data not shown).  
In addition, we investigated the ability of selected clones to modulate in vitro 
angiogenesis in the rat aortic ring assay. Rat aortic rings were embedded in a collagen gel and 
maintained in MCDB supplemented with media conditioned by transfectants (1/6, v/v). After 6 
days of incubation, computer-assisted image analysis was applied to determine geometrical and 
morphological parameters (number of vessels = Nv and maximal length of vessels = Lmax) 
(27). These parameters did not differ in aortic ring cultures supplemented with medium 
conditioned by cells expressing or not MT4-MMP (Nv = 26.5 +/- 5 for MT4-MMP clones vs 
29 +/- 2 for control clones; Lmax = 614 µm +/- 46 for MT4 clones vs 543 µm +/- 40 for control 
clones). 
MT4-MMP over-expression promotes in vivo primary tumor growth 
RAG-1 immunodeficient mice were subcutaneously injected with the different MT4-
MMP expressing or control clones in 3 separate sets of experiments. Tumor incidence and 
tumor growth were monitored from the third to the sixth week after injection. MT4-MMP over-
expression resulted in increased tumor incidence and tumor growth (Fig. 3B, C). At day 45, 
tumor incidence was 96 % (46/48 tumors) in MT4-MMP expressing tumors and 50 % (19/38 
tumors) in control tumors. Thirty-two days after cell injection, all tumors expressing MT4-
MMP reached higher volumes as compared to control tumors (P < 0.05) (Fig. 3B, C). When 
 - 14 - 
considering all independent experiments together, the mean tumor volumes reached at the end 
of the assays ranged from 639 to 1340 mm3 for MT4-MMP-transfected cells, and from 54 to 
486 mm3 for control clones (P < 0.05). 
Considering the previously described involvement of MT1-MMP in tumor angiogenesis 
(25), we further investigated whether MT4-MMP could affect tumor vascularization (Fig. 4B). 
No obvious difference in vessel density was detected between experimental groups. However, 
interestingly, MT4-MMP production affected vessel shape and size leading to an important 
enlargement of intratumoral blood vessels.  Immunostaining for α-SMA revealed the presence 
of pericytes surrounding enlarged vessels of MT4-MMP expressing tumors, as well as 
collapsed and small vessels presenting a lumen in control tumors (Fig. 4C).   
MT4-MMP over-expression is associated with an induction of lung metastases  
Metastatic ability of all transfectants injected in RAG-1 -/- mice was assessed by 
histochemical and immunohistochemical analyses of lungs harvested 45 days after tumor cell 
inoculation. Numerous metastatic nodules were easily distinguishable in lungs of mice 
inoculated with MT4-MMP-expressing cells, but not in those of mice injected with control 
clones (Fig. 5A). In order to detect small metastatic foci, lung sections were immunostained 
with an antibody raised against human Ki-67 protein and detecting proliferative cancer cells 
(Fig. 5A, B). Incidence and severity of metastases were determined by considering the size of 
metastatic foci (number of cells/foci) (Table I). All clones over-expressing MT4-MMP induced 
lung metastasis in 100 % of injected animals. In sharp contrast, when considering control 
clones, metastasis incidence varied from 0 % to 100 % (Table IA). The severity of metastases 
was also strongly increased in mice injected with MT4-MMP expressing cells. Score 3° 
metastatic nodules (composed of more than 20 cells) were only detected after injection of 
MT4-MMP transfectants (Table I and Fig. 5A), while metastatic foci induced by inoculation of 
control clones were scored 1° (dispersed cells) or 2° (composed of less than 20 cells). In 
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addition, MT4-MMP transfectants showed a significant increase in the number of metastatic 
foci (P < 0.05) (Fig. 5D). When considering all clones together, it clearly appeared that both 
incidence and severity of metastasis were significantly higher in mice injected with MT4-MMP 
expressing clones as compared to control clones (P < 0.001). Immunohistochemistry further 
confirmed MT4-MMP expression in lung metastases produced by MT4-MMP transfected 
clones (Fig. 5C) as well as in the corresponding primary tumors (Fig. 4A).  
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DISCUSSION  
 We investigated the potential implication of the GPI-anchored MT4-MMP in breast 
cancer progression. This study provides the first direct evidence for a pivotal role of MT4-
MMP in primary breast cancer growth leading to metastatic dissemination. Several lines of 
evidence support these conclusions. First, MT4-MMP is produced at higher levels in human 
breast cancer tissues than in normal breasts. Second, MT4-MMP over-expression in MDA-
MB-231 cells resulted in an enhanced tumor incidence, in an acceleration of primary tumor 
growth with subsequent apparition of lung metastases and in an enlargement of intratumoral 
blood vessels. Third, the involvement of MT4-MMP in metastatic dissemination is suggested 
by its expression in human metastatic cells originating from human breast cancers.  
Quantitative RT-PCR analyses were first performed on human normal breast and 
mammary adenocarcinoma samples. MT4-MMP mRNA was found expressed in all human 
breast adenocarcinoma samples, but at similar levels as in normal breast samples. However, 
interestingly, immunohistochemical analyses revealed a very high and homogenous production 
of MT4-MMP protein in human breast adenocarcinomas and metastatic lymph nodes, which is 
consistent with its original isolation from a human breast adenocarcinoma source (19). While 
MT1-MMP was described as a stromal MMP (32-34), MT4-MMP expression appears 
restricted to cancerous epithelial cells with some staining in inflammatory cells. Quantitative 
analysis revealed a 3 to 4 fold increase of MT4-MMP staining density and intensity in tumor 
samples as compared to normal breast tissues in which a faint and irregular immunostaining 
was observed. The absence of a correlation between MT4-MMP mRNA levels and tumor 
development might appear disappointing. However, this observation is consistent with previous 
studies performed on human prostate cancers (21) and mammary carcinomas of PyMT mice 
(transgenic for polyoma virus middle T antigen under the control of the MMTV promoter) 
(35). The discrepancy between RT-PCR and immunohistochemical results could be related to 
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mRNA heterogeneities of samples used for total RNA extractions, while tissue sections allow a 
better localization of the molecule of interest. In addition, MT4-MMP production could be 
controlled at post-transcriptional and/or post-translational levels. Increased production of MT4-
MMP in tumors could be related to modification of mRNA translation rate or reduction of 
MT4-MMP degradation, cell surface shedding and/or internalization. Evidences exist 
indicating that members of MT-MMP subfamily can be internalized (36, 37) or shed from the 
cell membrane (5, 38). Dissection of molecular mechanisms leading to a regulation of MT4-
MMP protein requires further investigations. Therefore the increased MT4-MMP protein 
production in human breast adenocarcinomas might suggest a specific function of MT4-MMP 
in human breast cancer progression and prompted us to evaluate the effect of MT4-MMP over-
expression in human breast cancer cell lines.  
We next transfected human breast cancer MDA-MB-231 cells with MT4-MMP cDNA. 
Four clones stably expressing this MT-MMP and four control clones were characterized in 
vitro and in vivo. Although MT4-MMP over-expression in MDA-MB-231 cells does not 
significantly affect their in vitro proliferation or in vitro invasiveness in the different matrices 
tested, it strongly increases their in vivo tumorigenicity with subsequent apparition of lung 
metastases when subcutaneously injected into RAG-1 immunodeficient mice. Using human Ki-
67 protein as an indicator of metastasis (30), we indeed observed that MT4-MMP over-
expression was associated with an increase of both the number and severity of lung metastases. 
MT1-MMP (39) and pro-MMP-2 (40) over-expressed in cancer cells were already reported to 
increase experimental lung metastases by intra-venous and intra-cardiac injections, 
respectively. Here, we demonstrate that MT4-MMP over-expressed in breast cancer cells can 
lead directly or indirectly to in vivo lung metastases after subcutaneous injection. In addition to 
establishing a new association between MT-MMPs and cancer, our MT4-MMP transfected 
cells provide a relevant model of lung metastases from primary tumor and involving all steps 
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implicated in metastatic dissemination such as intravastion, extravasation, and migration (41). 
Further studies are required to determine which steps of cancer progression are affected by 
MT4-MMP. 
The molecular mechanisms of MT4-MMP action in tumor progression are unknown. Its 
localization at the cell surface raised the possibility that it controls pericellular proteolysis and 
participates directly or indirectly to intracellular signaling events. Alternatively, MT4-MMP 
could be involved in tissue remodeling associated to tumor growth and metastatic spread of 
cancer cells. In this context, it is worth noting that a role for MT4-MMP in cartilage 
aggrecanolysis through ADAMTS-4 activation has been described (22). In addition, 
interleukine-1 (IL-1) has been shown to induce MT4-MMP with subsequent processing of 
ADAMTS-4 in IL-1-mediated aggrecanolysis of bovine cartilage (23). As assessed by qRT-
PCR, no ADAMTS-4 mRNAs were detected in our cultured transfectants or their 
corresponding in vivo xenografts (data not shown). Nevertheless, the lack of ADAMTS-4 
detection in established primary tumors does not negate the possibility that an ADAMTS-
4/MT4-MMP pathway contributes to earlier steps of cancer development. In addition, we can 
not exclude a possible implication of this pathway in host-tumor interface in tumor and 
metastases microenvironments.  
Shedding of MT4-MMP offers an alternative way to contribute to biological processes 
at a distance from the producing cells. Indeed, in accordance with the data of Itoh et al. (38), 
we detected large amounts of MT4-MMP protein shed in the supernatant of cells expressing 
MT4-MMP (data not shown). In contrast to our and other data previously reported for MT1-
MMP (10, 25), the tumor promoting effect of MT4-MMP could not be associated to higher in 
vitro invasive capacities, as assessed in Boyden chamber assays using matrigel and collagen 
matrices. In addition, consistent with the previous report of English et al. (16), MT4-MMP 
production does not affect the in vitro capacity to activate exogenous pro-MMP-2, known to 
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participate in cell invasion. These observations suggest that MT4-MMP does not contribute to 
cell invasion through direct extracellular matrix degradation or that it could degrade some 
substrates via other molecules that are absent in vitro. Alternatively, in vivo MT4-MMP 
activities could require other factors, such as for instances, inflammatory mediators or growth 
factors (16, 19). Our original findings of MT4-MMP protein over-production by epithelial 
cancerous cells of breast adenocarcinomas and metastastic lymph nodes, in addition to its 
detection in inflammatory cells [the present study and (16, 19, 42)] extend the putative 
functions of MT4-MMP and suggest a dual role in both inflammatory responses and cancer 
processes for MT4-MMP.  
The higher in vivo tumor growth induced by MT4-MMP expression could not be 
explained by a direct angiogenic effect as described for MT1-MMP (13, 25). We previously 
reported that MT1-MMP tumor promoting effect could be linked, at least in part, to an up-
regulation of VEGF at a transcriptional levels (12). However, in contrast to MT1-MMP, MT4-
MMP over-expressed in breast cancer cells fails to increase in vitro VEGF expression. In 
addition, medium conditioned by transfected cells is not able to enhance in vitro angiogenesis 
in the aortic ring assay. Nevertheless, MT4-MMP production modulates vasculature 
architecture. In vivo, MT4-MMP induces enlargement of intratumoral blood vessels which 
were covered by pericytes reflecting their maturity (43). Altogether, our findings suggest that 
MT4-MMP contribution to cancer progression involves other pathways that those activated by 
MT1-MMP.  
In conclusion, our data clearly demonstrate a pivotal role of MT4-MMP in human 
breast cancer growth ending up to metastatic dissemination. Both MT1- and MT4-MMPs 
contribute to cancer progression, but their mechanisms of action are divergent. These findings 
have direct implication for development of new anti-cancer strategies by highlighting the 
importance to target different MT-MMPs. 
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 A) Incidence of lung metastasis  B) Average number of lung metastatic nodules/section 
(mean [range] ) 
  Severity of metastasis  Severity of metastasis  
Clones Incidence 
n/n    (%) 
1° 2° 3°  1° 2° 3° 
            
M2 5/5   (100%) 5/5 1/5 0/5  19.4 [7-46] 0.2 [0-1] 0 - 
M3 5/5   (100%) 5/5 5/5 3/5  75 [18-169] 86.4 [5-231] 13 [0-43] 
M10 5/5   (100%) 5/5 1/5 2/5  93.8 [4-416] 80.2 [0-401] 7 [0-34] 
M14 
 
5/5   (100%) 5/5 4/5 2/5  82 [5-309] 41.2 [0-108] 2 [0-8] 
C4 0/5   (0%) 0/5 0/5 0/5  0 - 0 - 0 - 
C12 2/5   (40%) 2/5 2/5 0/5  14.2 [0-68] 4 [0-19] 0 - 
C14 3/5   (60%) 3/5 2/5 0/5  4.2 [0-19] 0.8 [0-3] 0 - 
C15 5/5   (100%) 5/5 2/5 0/5  7 [2-15] 0.4 [0-1] 0 - 
            
 
Table I. Effect of MT4-MMP on incidence and severity of lung metastasis in RAG-1 -/- mice 
bearing subcutaneous tumors of MDA-MB-231 clones. Four MDA-MB-231 clones 
transfected with MT4-MMP (clones M) or with vector control (clones C) were 
subcutaneously injected (1 x 106 cells/injection) into RAG-1 -/- mice (5 mice/clone). Mouse 
lung tissue sections were immuno-stained for human KI-67 protein. Metastatic foci were 
counted in 65 histological fields (5 mice/clone) at 200-fold magnification. The incidence of 
metastasis (A) is expressed as the percentage of mice with detectable metastatic cells in the 
lungs. Severity of metastasis was scored as follows: minimal (1° = metastatic nodule 
involving less than 3 stained cells), medium (2° = metastatic nodule composed of 3 to 20 
stained cells), or extensive involvement (3° = metastatic nodule including more than 20 
stained cells). Cells expressing MT4-MMP showed a significant increase of metastasis 
incidence (P < 0.001). Number and severity of metastasis is expressed as the mean with the 
range for each transfectant groups (B). 
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LEGEND TO FIGURES 
Figure 1. Expression of MT4-MMP in human breast adenocarcinomas. A), Relative mRNA 
expression level of MT4-MMP in 63 breast cancer and 21 normal breast samples assessed by 
qRT-PCR. Results are expressed as ratios of MT4-MMP mRNA to 18S rRNA levels. Bars 
represent median. B), Immunohistochemical detection of MT4-MMP in human breast 
adenocarcinoma, normal breast, metastatic and normal lymph nodes. Breast tumor sections 
(“breast carcinoma”) displayed a strong and extensive MT4-MMP production in tumor cells 
(t), but not in the surrouding stroma (s).White arrow: myoepithelial cells; a: adipocytes; s: 
stroma; t: tumor cells; l: lymphocytes; d: ducts; m: metastatic cells; ca: node capsule; gc: 
germinal center; co: cortex. Photomicrographs at 400 fold-magnification (scale bar = 50 µm) 
and 100 fold-magnification (scale bar = 200 µm) for left and right panels, respectively. C), 
Quantification of MT4-MMP immunostaining. Average staining density (higher panel) and 
staining intensity (lower panel) were determined on 25 representative sections of each group 
as described in Material and Methods section. Error bars represent SE (*** P < 0.001).  
 
Figure 2. Analysis of MT4-MMP expression in MDA-MB-231 clones stably transfected with 
MT4-MMP cDNA (M2, M3, M10, M14) or with pcDNA3-neo control vector (C4, C12, C14, 
C15). A), RT-PCR analysis of MT4-MMP mRNA level. Expression of 28S rRNA is shown as 
loading control. B), Western blot analysis of MT4-MMP protein. Total protein extracts of 
clones were analyzed using an anti-human MT4-MMP sheep polyclonal antibody raised 
against MT4-MMP catalytic domain. Actin production level in transfectants is shown as 
loading control.    
 
Figure 3. Characterization of in vitro and in vivo properties of four MDA-MB-231 clones 
stably transfected with MT4-MMP cDNA (black symbols, continued lines, clones M) or with 
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pcDNA3-neo control vector (white symbols, dotted lines, clones C). A), In vitro growth 
curves of transfectants. Clones were seeded in triplicate in 24-well plates and harvested each 
day for DNA content evaluation. Results, expressed as mean of DNA concentration of 
triplicates +/- SE, are those of one representative experiment out of 3. B) and C), In vivo 
tumor growth curves of the transfectants. Clones were subcutaneously injected into RAG-1 -/- 
mice in three independent assays and tumor volumes were assessed as described in Material 
and Methods. Data shown are those of 2 representative independent experiments, in which 
MT4-MMP clones (M2, M3, M14 in B; M2, M3, M10 in C) and control clones (C4, C12, C15 
in B; C4, C14 in C) were tested. Results are expressed as mean of tumor volumes for each 
experimental group +/- SE (*** P < 0.001; ** P < 0.01; * P < 0.05). 
 
Figure 4. Immunohistochemical analysis of primary tumors. Tumors were induced by 
subcutaneous injection of MT4-MMP transfected MDA-MB-231 clones (MT4 clones, left 
side) or control clones (CTR clones, right side) into RAG-1 -/- mice. Tumor sections were 
immunostained by using antibodies raised against: A), MT4-MMP; B), von Willebrand factor 
(vWF); C), α- smooth muscle actin (SMA). Photomicrographs at 200 fold-magnification 
(scale bar = 100 µm). B and C represent serial sections for both experimental groups. 
 
Figure 5. Immunodetection and quantification of lung metastases. MDA-MB-231 clones 
expressing MT4-MMP (MT4 clones, left side) or not (CTR clones, right side) were 
subcutaneously injected into RAG-1 -/- mice (5 to 6 mice/clones) in two independent assays. 
At day 45, lungs were collected, formalin-fixed and parafin-embedded. A) and B), Metastatic 
nodules were immunodetected in lung tissue sections  with an antibody raised against human 
Ki-67 protein and scored 1° (white arrow), 2° (grey arrow) or 3° (black arrow) as described 
in Material and Methods. C), Immunostaining analysis confirmed MT4-MMP production in 
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metastases induced by MT4-MMP transfected cells (left side). Photomicrographs at 100 fold-
magnification in A (scale bar = 200 µm) or 200-fold magnification in B and C (scale bar = 
100 µm). B and C represent serial sections for both experimental groups. bv: blood vessel. D), 
For each clone, metastatic foci were counted in 65 histological fields at 200-fold 
magnification. Severity of metastasis was scored as illustrated in panel A. Results are 
expressed as the average number of metastatic nodules detected per mice for both 
experimental groups. Error bars represent SE. Cells transfected with MT4-MMP show a 
significant increase in number and severity of metastasis. Control clones never produced score 
3° metastasis (*** P < 0.001 and * P < 0.05). 





